Trastuzumab rezetecan - CAS 2924909-11-3

Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer.

EGFR, Antibody-Drug Conjugates (ADCs)

Angiogenesis, Antibody-drug Conjugate/ADC Related, JAK/STAT signaling, Tyrosine Kinase/Adaptors

2924909-11-3

-20°C

Ice Packs

Inhibitory Antibodies